Page last updated: 2024-08-03 11:39:52

pf-04691502

Description

Cross-References

ID SourceID
PubMed CID25033539
CHEMBL ID1234354
SCHEMBL ID1984896
SCHEMBL ID1381431
SCHEMBL ID1381425
SCHEMBL ID10092210
SCHEMBL ID13976989
MeSH IDM0571803

Synonyms (58)

Synonym
2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8h)-one
HY-15177
pf-4691502
pf-04691502 ,
CHEMBL1234354 ,
AKOS005266645
us8633204, 286
bdbm50380313
pf 04691502
pf04691502
4w39ns61ki ,
unii-4w39ns61ki
pyrido(2,3-d)pyrimidin-7(8h)-one, 2-amino-8-(trans-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxy-3-pyridinyl)-4-methyl-
BCP0726000275
1013101-36-4
NCGC00346659-01
CS-0919
S2743
2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8h)-one
2-amino-8-(cis-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8h)-one
2-amino-8-(cis-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8h)-one
XDLYKKIQACFMJG-IYBDPMFKSA-N
gtpl7936
SCHEMBL1984896
MLS006010979
smr004702782
SCHEMBL1381431
SCHEMBL1381425
SCHEMBL10092210
SCHEMBL13976989
2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7(8h)-one
AC-28429
2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
4TV3
J-000360
EX-A032
AKOS030257531
HMS3656B21
pf4691502
pf-04691502, >=98% (hplc)
trans-2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8h)-one
mfcd18782794
NCGC00381752-06
SW220185-1
DB11974
Q27088316
AS-17042
BCP02895
SB20066
2-amino-8-(rel-(1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8h)-one
CCG-268947
nsc-800846
nsc800846
nsc760536
nsc-760536
NCGC00381752-02
2-amino-8-(trans-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido(2,3-d)pyrimidin-7(8h)-one
DTXSID901026004

Protein Targets (294)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency1.4818AID1347053
PPM1D proteinHomo sapiens (human)Potency0.1171AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency0.0711AID1259252; AID1259253; AID1259255; AID1259256
GVesicular stomatitis virusPotency4.8040AID1645842
polyproteinZika virusPotency1.4818AID1347053
Interferon betaHomo sapiens (human)Potency1.9919AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency4.8040AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency4.8040AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency4.8040AID1645842

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)Ki0.0016AID1871782
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)IC500.0130AID744341
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)IC500.0067AID1069396; AID1188623; AID1355489
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)Ki0.0012AID1871780; AID656759
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Mus musculus (house mouse)Ki0.0006AID744343
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)Ki0.0021AID1871781
Serine/threonine-protein kinase mTORHomo sapiens (human)IC500.0079AID1069395; AID1188624
Serine/threonine-protein kinase mTORHomo sapiens (human)Ki0.0160AID656760; AID744342
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)Ki0.0019AID1871783

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Bone morphogenetic protein receptor type-1BHomo sapiens (human)Kd30.0000AID1424922
Membrane-associated progesterone receptor component 1Homo sapiens (human)Kd30.0000AID1425109
Cell division cycle 7-related protein kinaseHomo sapiens (human)Kd30.0000AID1424936
Serine/threonine-protein kinase PLK4Homo sapiens (human)Kd30.0000AID1425121
ATP-dependent RNA helicase DDX3XHomo sapiens (human)Kd30.0000AID1424975
Pyridoxal kinaseHomo sapiens (human)Kd30.0000AID1425106
Citron Rho-interacting kinaseHomo sapiens (human)Kd30.0000AID1424954
Serine/threonine-protein kinase Chk1Homo sapiens (human)Kd30.0000AID1424953
Aurora kinase AHomo sapiens (human)Kd30.0000AID1424917
Cyclin-G-associated kinaseHomo sapiens (human)Kd30.0000AID1425009
Ephrin type-B receptor 6Homo sapiens (human)Kd30.0000AID1424995
Peroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)Kd30.0000AID1424896
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)Kd30.0000AID1425155
Mitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)Kd30.0000AID1424926
Dynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)Kd30.0000AID1425097
Eukaryotic translation initiation factor 5BHomo sapiens (human)Kd30.0000AID1424986
Rho-associated protein kinase 2Homo sapiens (human)Kd30.0000AID1425158
Serine/threonine-protein kinase ULK1Homo sapiens (human)Kd30.0000AID1425208
Serine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)Kd30.0000AID1424997
Ribosomal protein S6 kinase alpha-5Homo sapiens (human)Kd30.0000AID1425162
U5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)Kd30.0000AID1425174
Ribosomal protein S6 kinase alpha-4Homo sapiens (human)Kd30.0000AID1425161
Serine/threonine-protein kinase 16Homo sapiens (human)Kd30.0000AID1425179
Serine/threonine-protein kinase 10Homo sapiens (human)Kd30.0000AID1425177
Serine/threonine-protein kinase D3Homo sapiens (human)Kd30.0000AID1425137
Structural maintenance of chromosomes protein 2Homo sapiens (human)Kd30.0000AID1425173
Mitogen-activated protein kinase kinase kinase 6Homo sapiens (human)Kd30.0000AID1425050
Mitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)Kd30.0000AID1425054
Serine/threonine-protein kinase LATS1Homo sapiens (human)Kd30.0000AID1425033
Serine/threonine-protein kinase PAK 4Homo sapiens (human)Kd30.0000AID1425100
Tyrosine-protein kinase ABL1Homo sapiens (human)Kd30.0000AID1424890
Epidermal growth factor receptorHomo sapiens (human)Kd30.0000AID1424983
High affinity nerve growth factor receptorHomo sapiens (human)Kd30.0000AID1425094
Guanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)Kd30.0000AID1425011
ADP/ATP translocase 2Homo sapiens (human)Kd30.0000AID1425169
Protein kinase C beta typeHomo sapiens (human)Kd30.0000AID1425130
Insulin receptorHomo sapiens (human)Kd30.0000AID1425026
Tyrosine-protein kinase LckHomo sapiens (human)Kd30.0000AID1425034
Tyrosine-protein kinase FynHomo sapiens (human)Kd30.0000AID1425008
Cyclin-dependent kinase 1Homo sapiens (human)Kd30.0000AID1424937
Glycogen phosphorylase, liver formHomo sapiens (human)Kd30.0000AID1425146
Tyrosine-protein kinase Fes/FpsHomo sapiens (human)Kd30.0000AID1425003
Adenine phosphoribosyltransferaseHomo sapiens (human)Kd30.0000AID1424914
Tyrosine-protein kinase YesHomo sapiens (human)Kd30.0000AID1425212
Tyrosine-protein kinase LynHomo sapiens (human)Kd30.0000AID1425037
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)Kd30.0000AID1425154
Insulin-like growth factor 1 receptorHomo sapiens (human)Kd30.0000AID1425022
Signal recognition particle receptor subunit alphaHomo sapiens (human)Kd30.0000AID1425176
Cytochrome c1, heme protein, mitochondrialHomo sapiens (human)Kd30.0000AID1424969
Tyrosine-protein kinase HCKHomo sapiens (human)Kd30.0000AID1425017
Platelet-derived growth factor receptor betaHomo sapiens (human)Kd30.0000AID1425104
Serine/threonine-protein kinase A-RafHomo sapiens (human)Kd30.0000AID1424915
Mast/stem cell growth factor receptor KitHomo sapiens (human)Kd30.0000AID1425032
Glycogen phosphorylase, brain formHomo sapiens (human)Kd30.0000AID1425145
Breakpoint cluster region proteinHomo sapiens (human)Kd30.0000AID1424919
Serine/threonine-protein kinase pim-1Homo sapiens (human)Kd30.0000AID1425111
Fibroblast growth factor receptor 1Homo sapiens (human)Kd30.0000AID1425004
DNA topoisomerase 2-alphaHomo sapiens (human)Kd30.0000AID1425202
Cyclin-dependent kinase 4Homo sapiens (human)Kd30.0000AID1424946
ADP/ATP translocase 3Homo sapiens (human)Kd30.0000AID1425170
Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)Kd30.0000AID1425025
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)Kd30.0000AID1425175
cAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)Kd30.0000AID1425128
Serine/threonine-protein kinase B-rafHomo sapiens (human)Kd30.0000AID1424924
Phosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)Kd30.0000AID1425110
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)Kd30.0000AID1425093
Tyrosine-protein kinase FerHomo sapiens (human)Kd30.0000AID1425002
Protein kinase C alpha typeHomo sapiens (human)Kd30.0000AID1425129
cAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)Kd30.0000AID1425123
General transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)Kd30.0000AID1424996
Casein kinase II subunit alpha'Homo sapiens (human)Kd1.5430AID1424968
Ras-related protein Rab-6AHomo sapiens (human)Kd30.0000AID1425150
Ephrin type-A receptor 1Homo sapiens (human)Kd30.0000AID1424987
Multifunctional protein ADE2Homo sapiens (human)Kd30.0000AID1425098
cAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)Kd30.0000AID1425125
cAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)Kd30.0000AID1425124
Ferrochelatase, mitochondrialHomo sapiens (human)Kd30.0000AID1425001
Ribosomal protein S6 kinase beta-1Homo sapiens (human)Kd30.0000AID1425164
Tyrosine-protein kinase JAK1Homo sapiens (human)Kd30.0000AID1425030
Cyclin-dependent kinase 2Homo sapiens (human)Kd30.0000AID1424944
Beta-adrenergic receptor kinase 1Homo sapiens (human)Kd30.0000AID1424908
Probable ATP-dependent RNA helicase DDX6Homo sapiens (human)Kd30.0000AID1424977
Mitogen-activated protein kinase 3 Homo sapiens (human)Kd30.0000AID1425061
MAP/microtubule affinity-regulating kinase 3Homo sapiens (human)Kd30.0000AID1425069
Deoxycytidine kinaseHomo sapiens (human)Kd30.0000AID1424970
Mitogen-activated protein kinase 1Homo sapiens (human)Kd30.0000AID1425056
Ephrin type-A receptor 2Homo sapiens (human)Kd30.0000AID1424988
Ephrin type-B receptor 2Homo sapiens (human)Kd30.0000AID1424992
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)Kd30.0000AID1425207
UMP-CMP kinase Homo sapiens (human)Kd30.0000AID1424959
Phosphatidylethanolamine-binding protein 1Homo sapiens (human)Kd30.0000AID1425107
Wee1-like protein kinaseHomo sapiens (human)Kd30.0000AID1425210
Heme oxygenase 2Homo sapiens (human)Kd30.0000AID1425018
S-adenosylmethionine synthase isoform type-2Homo sapiens (human)Kd30.0000AID1425071
DnaJ homolog subfamily A member 1Homo sapiens (human)Kd30.0000AID1424980
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)Kd30.0000AID1424910
RAC-beta serine/threonine-protein kinaseHomo sapiens (human)Kd30.0000AID1424911
DNA replication licensing factor MCM4Homo sapiens (human)Kd30.0000AID1425072
Myosin-10Homo sapiens (human)Kd30.0000AID1425079
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)Kd30.0000AID1425039
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)Kd30.0000AID1425006
Bone morphogenetic protein receptor type-1AHomo sapiens (human)Kd30.0000AID1424921
Activin receptor type-1BHomo sapiens (human)Kd30.0000AID1424901
TGF-beta receptor type-1Homo sapiens (human)Kd30.0000AID1425196
TGF-beta receptor type-2Homo sapiens (human)Kd30.0000AID1425197
Electron transfer flavoprotein subunit betaHomo sapiens (human)Kd30.0000AID1424999
Tyrosine-protein kinase CSKHomo sapiens (human)Kd30.0000AID1424960
Glycine--tRNA ligaseHomo sapiens (human)Kd30.0000AID1425010
Protein kinase C iota typeHomo sapiens (human)Kd30.0000AID1425133
Exosome RNA helicase MTR4Homo sapiens (human)Kd30.0000AID1425168
Tyrosine-protein kinase TecHomo sapiens (human)Kd30.0000AID1425193
Tyrosine-protein kinase ABL2Homo sapiens (human)Kd30.0000AID1424891
Tyrosine-protein kinase FRKHomo sapiens (human)Kd30.0000AID1425007
Tyrosine-protein kinase SYKHomo sapiens (human)Kd30.0000AID1425188
26S proteasome regulatory subunit 6BHomo sapiens (human)Kd30.0000AID1425141
Mitogen-activated protein kinase 8Homo sapiens (human)Kd30.0000AID1425063
Mitogen-activated protein kinase 9Homo sapiens (human)Kd30.0000AID1425064
Dual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)Kd30.0000AID1425040
Phosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)Kd30.0000AID1425113
Casein kinase I isoform alphaHomo sapiens (human)Kd30.0000AID1424961
Casein kinase I isoform deltaHomo sapiens (human)Kd30.0000AID1424962
MAP kinase-activated protein kinase 2Homo sapiens (human)Kd30.0000AID1425065
Elongation factor Tu, mitochondrialHomo sapiens (human)Kd30.0000AID1425206
Choline-phosphate cytidylyltransferase AHomo sapiens (human)Kd30.0000AID1425103
Cysteine--tRNA ligase, cytoplasmicHomo sapiens (human)Kd30.0000AID1424932
Casein kinase I isoform epsilonHomo sapiens (human)Kd30.0000AID1424963
Very long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)Kd30.0000AID1424894
Dual specificity protein kinase CLK1Homo sapiens (human)Kd30.0000AID1424955
Dual specificity protein kinase CLK2Homo sapiens (human)Kd30.0000AID1424956
Glycogen synthase kinase-3 alphaHomo sapiens (human)Kd30.0000AID1425013
Glycogen synthase kinase-3 betaHomo sapiens (human)Kd30.0000AID1425014
Cyclin-dependent kinase 7Homo sapiens (human)Kd30.0000AID1424949
Cyclin-dependent kinase 9Homo sapiens (human)Kd30.0000AID1424950
Ras-related protein Rab-27AHomo sapiens (human)Kd30.0000AID1425149
Interleukin-1 receptor-associated kinase 1Homo sapiens (human)Kd30.0000AID1425027
Ribosomal protein S6 kinase alpha-3Homo sapiens (human)Kd30.0000AID1425160
Serine/threonine-protein kinase Nek2Homo sapiens (human)Kd30.0000AID1425086
Serine/threonine-protein kinase Nek3Homo sapiens (human)Kd30.0000AID1425087
Dual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)Kd30.0000AID1425043
LIM domain kinase 1Homo sapiens (human)Kd30.0000AID1425035
LIM domain kinase 2Homo sapiens (human)Kd30.0000AID1425036
Mitogen-activated protein kinase 10Homo sapiens (human)Kd30.0000AID1425057
Tyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)Kd30.0000AID1425211
5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)Kd30.0000AID1425126
Ephrin type-B receptor 3Homo sapiens (human)Kd30.0000AID1424993
Ephrin type-A receptor 5Homo sapiens (human)Kd30.0000AID1424990
Ephrin type-B receptor 4Homo sapiens (human)Kd30.0000AID1424994
Ephrin type-A receptor 4Homo sapiens (human)Kd30.0000AID1424989
Adenylate kinase 2, mitochondrialHomo sapiens (human)Kd30.0000AID1424909
Adenosine kinaseHomo sapiens (human)Kd30.0000AID1424907
Ras-related protein Rab-10Homo sapiens (human)Kd30.0000AID1425148
Actin-related protein 3Homo sapiens (human)Kd30.0000AID1424899
Actin-related protein 2Homo sapiens (human)Kd30.0000AID1424898
GTP-binding nuclear protein RanHomo sapiens (human)Kd30.0000AID1425153
Casein kinase I isoform gamma-2Homo sapiens (human)Kd30.0000AID1424965
Cyclin-dependent kinase 3Homo sapiens (human)Kd30.0000AID1424945
Cyclin-dependent kinase 6Homo sapiens (human)Kd30.0000AID1424948
Cyclin-dependent-like kinase 5 Homo sapiens (human)Kd30.0000AID1424947
Cyclin-dependent kinase 16Homo sapiens (human)Kd30.0000AID1424941
ATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)Kd30.0000AID1425108
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)Kd30.0000AID1425038
DNA topoisomerase 2-betaHomo sapiens (human)Kd30.0000AID1425203
Protein kinase C theta typeHomo sapiens (human)Kd30.0000AID1425134
Activin receptor type-1Homo sapiens (human)Kd30.0000AID1424900
Macrophage-stimulating protein receptorHomo sapiens (human)Kd30.0000AID1425078
Focal adhesion kinase 1Homo sapiens (human)Kd30.0000AID1425142
Protein kinase C delta typeHomo sapiens (human)Kd30.0000AID1425131
Tyrosine-protein kinase BTKHomo sapiens (human)Kd30.0000AID1424925
Activated CDC42 kinase 1Homo sapiens (human)Kd30.0000AID1425201
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)Kd30.0000AID1424972
Mitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)Kd30.0000AID1425052
Serine/threonine-protein kinase 4Homo sapiens (human)Kd30.0000AID1425185
5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)Kd30.0000AID1425122
Dual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)Kd30.0000AID1425042
Mitogen-activated protein kinase 7Homo sapiens (human)Kd30.0000AID1425062
Serine/threonine-protein kinase PAK 2Homo sapiens (human)Kd30.0000AID1425099
Serine/threonine-protein kinase 3Homo sapiens (human)Kd30.0000AID1425182
Mitogen-activated protein kinase kinase kinase 1Homo sapiens (human)Kd30.0000AID1425044
Rho-associated protein kinase 1Homo sapiens (human)Kd30.0000AID1425157
Non-receptor tyrosine-protein kinase TNK1Homo sapiens (human)Kd30.0000AID1425200
Calcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)Kd30.0000AID1424929
Calcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)Kd30.0000AID1424928
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)Kd30.0000AID1424981
Activin receptor type-2BHomo sapiens (human)Kd30.0000AID1424902
Bone morphogenetic protein receptor type-2Homo sapiens (human)Kd30.0000AID1424923
Protein-tyrosine kinase 6Homo sapiens (human)Kd30.0000AID1425144
cGMP-dependent protein kinase 1 Homo sapiens (human)Kd30.0000AID1425138
Cyclin-dependent kinase 13Homo sapiens (human)Kd30.0000AID1424940
Inhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)Kd30.0000AID1425023
Protein-tyrosine kinase 2-betaHomo sapiens (human)Kd30.0000AID1425143
Maternal embryonic leucine zipper kinaseHomo sapiens (human)Kd30.0000AID1425074
Structural maintenance of chromosomes protein 1AHomo sapiens (human)Kd30.0000AID1425172
Chromodomain-helicase-DNA-binding protein 4Homo sapiens (human)Kd30.0000AID1424952
Serine/threonine-protein kinase 38Homo sapiens (human)Kd30.0000AID1425183
Ephrin type-A receptor 7Homo sapiens (human)Kd30.0000AID1424991
Delta(24)-sterol reductaseHomo sapiens (human)Kd30.0000AID1424978
Ribosomal protein S6 kinase alpha-1Homo sapiens (human)Kd30.0000AID1425159
Myosin light chain kinase, smooth muscleHomo sapiens (human)Kd30.0000AID1425081
Mitogen-activated protein kinase 11Homo sapiens (human)Kd30.0000AID1425058
Serine/threonine-protein kinase STK11Homo sapiens (human)Kd30.0000AID1425178
Serine/threonine-protein kinase N1Homo sapiens (human)Kd30.0000AID1425117
Serine/threonine-protein kinase N2Homo sapiens (human)Kd30.0000AID1425118
Mitogen-activated protein kinase 14Homo sapiens (human)Kd30.0000AID1425059
Calcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)Kd30.0000AID1424930
Mitogen-activated protein kinase kinase kinase 11Homo sapiens (human)Kd30.0000AID1425045
Discoidin domain-containing receptor 2Homo sapiens (human)Kd30.0000AID1424973
AP2-associated protein kinase 1Homo sapiens (human)Kd30.0000AID1424889
Myosin light chain kinase 3Homo sapiens (human)Kd30.0000AID1425082
Putative heat shock protein HSP 90-beta 2Homo sapiens (human)Kd30.0000AID1425019
Rab-like protein 3Homo sapiens (human)Kd30.0000AID1425151
Serine/threonine-protein kinase MRCK alphaHomo sapiens (human)Kd30.0000AID1424933
Serine/threonine-protein kinase MRCK gammaHomo sapiens (human)Kd30.0000AID1424935
Acyl-CoA dehydrogenase family member 10Homo sapiens (human)Kd30.0000AID1424892
Serine/threonine-protein kinase ULK3Homo sapiens (human)Kd30.0000AID1425209
Uncharacterized protein FLJ45252Homo sapiens (human)Kd30.0000AID1425147
Acyl-CoA dehydrogenase family member 11Homo sapiens (human)Kd30.0000AID1424893
Serine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)Kd30.0000AID1424998
Serine/threonine-protein kinase MARK2Homo sapiens (human)Kd30.0000AID1425068
Serine/threonine-protein kinase TAO1Homo sapiens (human)Kd30.0000AID1425189
STE20-related kinase adapter protein alphaHomo sapiens (human)Kd30.0000AID1425186
Myosin-14Homo sapiens (human)Kd30.0000AID1425080
AarF domain-containing protein kinase 1Homo sapiens (human)Kd30.0000AID1424904
ATP-dependent RNA helicase DDX42Homo sapiens (human)Kd30.0000AID1424976
Mitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)Kd30.0000AID1425053
MAP kinase-activated protein kinase 5Homo sapiens (human)Kd30.0000AID1425067
Atypical kinase COQ8A, mitochondrialHomo sapiens (human)Kd30.0000AID1424905
Phosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)Kd30.0000AID1425115
Mitogen-activated protein kinase 15Homo sapiens (human)Kd30.0000AID1425060
Serine/threonine-protein kinase Nek9Homo sapiens (human)Kd30.0000AID1425089
Serine/threonine-protein kinase Nek7Homo sapiens (human)Kd30.0000AID1425088
ATP-dependent RNA helicase DDX1Homo sapiens (human)Kd30.0000AID1424974
Mitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)Kd30.0000AID1425051
Aurora kinase BHomo sapiens (human)Kd30.0000AID1424918
MAP/microtubule affinity-regulating kinase 4Homo sapiens (human)Kd30.0000AID1425070
Serine/threonine-protein kinase Nek1Homo sapiens (human)Kd30.0000AID1425085
PAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)Kd30.0000AID1425102
Calcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)Kd30.0000AID1424931
EKC/KEOPS complex subunit TP53RKHomo sapiens (human)Kd30.0000AID1425204
Dual specificity testis-specific protein kinase 2Homo sapiens (human)Kd30.0000AID1425195
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)Kd30.0000AID1425116
Mitogen-activated protein kinase kinase kinase 5Homo sapiens (human)Kd30.0000AID1425049
Mitogen-activated protein kinase kinase kinase 3Homo sapiens (human)Kd30.0000AID1425047
Eukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)Kd30.0000AID1424984
Nucleolar GTP-binding protein 1Homo sapiens (human)Kd30.0000AID1425016
Serine/threonine-protein kinase D2Homo sapiens (human)Kd30.0000AID1425136
RNA cytidine acetyltransferaseHomo sapiens (human)Kd30.0000AID1425083
Serine/threonine-protein kinase SIK2Homo sapiens (human)Kd30.0000AID1425166
STE20-like serine/threonine-protein kinase Homo sapiens (human)Kd30.0000AID1425171
Serine/threonine-protein kinase TAO3Homo sapiens (human)Kd30.0000AID1425191
dCTP pyrophosphatase 1Homo sapiens (human)Kd30.0000AID1424971
Phenylalanine--tRNA ligase beta subunitHomo sapiens (human)Kd30.0000AID1425000
Isoleucine--tRNA ligase, mitochondrialHomo sapiens (human)Kd30.0000AID1425020
BMP-2-inducible protein kinaseHomo sapiens (human)Kd30.0000AID1424920
Obg-like ATPase 1Homo sapiens (human)Kd30.0000AID1425096
MidasinHomo sapiens (human)Kd30.0000AID1425073
Interleukin-1 receptor-associated kinase 4Homo sapiens (human)Kd30.0000AID1425029
Mitogen-activated protein kinase kinase kinase 20Homo sapiens (human)Kd30.0000AID1425213
Cyclin-dependent kinase 12Homo sapiens (human)Kd30.0000AID1424939
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)Kd30.0000AID1425084
Serine/threonine-protein kinase 26Homo sapiens (human)Kd30.0000AID1425181
Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)Kd30.0000AID1425187
Serine/threonine-protein kinase NLKHomo sapiens (human)Kd30.0000AID1425090
5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)Kd30.0000AID1425127
Serine/threonine-protein kinase TBK1Homo sapiens (human)Kd30.0000AID1425192
Septin-9Homo sapiens (human)Kd30.0000AID1425165
Ribosomal protein S6 kinase alpha-6Homo sapiens (human)Kd30.0000AID1425163
TRAF2 and NCK-interacting protein kinaseHomo sapiens (human)Kd30.0000AID1425199
Serine/threonine-protein kinase TAO2Homo sapiens (human)Kd30.0000AID1425190
Serine/threonine-protein kinase ICKHomo sapiens (human)Kd30.0000AID1425021
RAC-gamma serine/threonine-protein kinaseHomo sapiens (human)Kd30.0000AID1424912
Serine/threonine-protein kinase SIK3Homo sapiens (human)Kd30.0000AID1425167
Mitogen-activated protein kinase kinase kinase 2Homo sapiens (human)Kd30.0000AID1425046
Mitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)Kd30.0000AID1425055
Receptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)Kd30.0000AID1425156
Serine/threonine-protein kinase MRCK betaHomo sapiens (human)Kd30.0000AID1424934
Interleukin-1 receptor-associated kinase 3Homo sapiens (human)Kd30.0000AID1425028
Serine/threonine-protein kinase 24Homo sapiens (human)Kd30.0000AID1425180
Casein kinase I isoform gamma-3Homo sapiens (human)Kd30.0000AID1424966
Mitogen-activated protein kinase kinase kinase 4Homo sapiens (human)Kd30.0000AID1425048

Bioassays (367)

Assay IDTitleYearJournalArticle
AID1424997Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424988Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424922Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425065Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424915Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425013Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424891Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425165Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425203Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424937Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425159Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425154Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425106Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424907Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425062Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424936Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425128Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425049Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425164Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424956Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425102Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425131Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424993Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424918Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1871782Inhibition of PI3Kdelta (unknown origin) expressed in baculovirus expression system using L-alpha-phosphatidylinositol as substrate by luminescence assay2022European journal of medicinal chemistry, Jan-15, Volume: 228ISSN: 1768-3254Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.
AID1425072Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425130Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425186Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425138Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425052Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425150Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425174Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1188624Inhibition of mTOR (unknown origin) assessed as inhibition of 4EBP-1 phosphorylation preincubated for 15 mins before substrate addition by TR-FRET assay2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
ISSN: 1464-3405
Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
AID1424955Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424935Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424966Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425196Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424925Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425167Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425109Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425000Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425002Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425073Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425195Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1355489Inhibition of PI3Kalpha (unknown origin) using PIP2 as substrate by Kinase-Glo assay2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
ISSN: 1520-4804
Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.
AID1425033Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425042Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425016Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424924Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425023Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425038Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425039Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424954Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1188628Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM after 90 mins by LC/MS/MS analysis2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
ISSN: 1464-3405
Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
AID1424892Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424967Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425006Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425089Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1871781Inhibition of PI3Kbeta (unknown origin) expressed in baculovirus expression system using L-alpha-phosphatidylinositol as substrate by luminescence assay2022European journal of medicinal chemistry, Jan-15, Volume: 228ISSN: 1768-3254Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.
AID1424948Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424968Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425064Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424920Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425181Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425108Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425171Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424971Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425096Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425043Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425047Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1069395Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
ISSN: 1464-3405
Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors.
AID1424959Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424990Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425156Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424931Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425113Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425175Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1355605Potency index, ratio of IC50 for PF-04691502 to IC50 for test compound for inhibition of PI3Kalpha (unknown origin) using PIP2 as substrate by Kinase-Glo assay2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
ISSN: 1520-4804
Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.
AID1425036Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425162Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424917Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425097Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425021Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425118Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425081Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425202Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425168Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424992Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425211Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425176Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424991Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1188625Antiproliferative activity against human SKOV3 cells after 3 days by CellTiter-Glo assay2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
ISSN: 1464-3405
Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
AID1425201Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID656759Inhibition of PI3Kalpha2011ACS medicinal chemistry letters, Nov-10, Volume: 2, Issue:11
ISSN: 1948-5875
Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.
AID1424889Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425146Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425011Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424972Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425126Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424995Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425183Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425009Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1871780Inhibition of PI3Kalpha (unknown origin) expressed in baculovirus expression system using L-alpha-phosphatidylinositol as substrate by luminescence assay2022European journal of medicinal chemistry, Jan-15, Volume: 228ISSN: 1768-3254Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.
AID1425143Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425098Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424978Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425170Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424890Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424976Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425140Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424965Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424921Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425200Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425190Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1850138Antibacterial activity against Bacillus subtilis 168 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two-fold serial dilution assay2022RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1
ISSN: 2632-8682
Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1425107Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425110Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425093Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425044Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425145Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID744330Drug metabolism in human plasma assessed as formation of 2-((trans)-4-(2-amino-6-(6-methoxypyridin-3-yl)-4-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyloxy)acetic acid at 8 mg, po qd for 21 days by HPLC analysis2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
ISSN: 1464-3405
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
AID1425027Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1388808Antiproliferative activity against human U87MG cells after 4 days by Celltiter-Glo luminescence cell viability assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
ISSN: 1464-3391
Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors.
AID1425103Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424963Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425059Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425088Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425144Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424901Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425136Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424905Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425058Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1355542Antitumor activity against human NCI-H460 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 10 mg/kg, po administered once daily after 20 days relative to control2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
ISSN: 1520-4804
Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.
AID1424969Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425185Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424949Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425155Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424989Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425115Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425147Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425037Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1850139Antibacterial activity against Staphylococcus aureus 29213 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method2022RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1
ISSN: 2632-8682
Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1424929Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425127Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425104Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424973Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1069396Inhibition of PI3Kalpha (unknown origin) using PIP2/PS as substrate compound preincubated for 15 mins by luciferase-based luminescence assay2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
ISSN: 1464-3405
Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors.
AID1425125Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425083Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425071Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424953Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425067Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424896Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424950Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425158Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425188Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425160Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424970Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424893Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1188626Antiproliferative activity against human U87MG cells after 4 days by CellTiter-Glo assay2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
ISSN: 1464-3405
Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
AID1425045Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425056Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424961Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425166Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424981Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425169Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425051Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425172Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424934Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425199Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424908Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424904Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424930Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425212Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1188627Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM after 90 mins by LC/MS/MS analysis2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
ISSN: 1464-3405
Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
AID1425086Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID744341Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
ISSN: 1464-3405
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
AID1425161Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425061Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425133Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424919Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424902Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1355561Toxicity in human NCI-H460 cells xenografted BALB/c nude mouse assessed as reduction in body weight at 10 mg/kg, po administered once daily after 20 days2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
ISSN: 1520-4804
Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.
AID1424975Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425099Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425213Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425084Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425124Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424933Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424939Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424945Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425019Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424947Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425189Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425035Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424994Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424910Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID656760Inhibition of mTOR2011ACS medicinal chemistry letters, Nov-10, Volume: 2, Issue:11
ISSN: 1948-5875
Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.
AID1424926Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424985Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID744342Inhibition of mTOR (unknown origin)2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
ISSN: 1464-3405
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
AID1424996Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425134Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425068Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425180Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424980Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425090Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425151Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425192Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425010Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425148Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424928Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425025Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425206Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424911Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425020Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425210Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425141Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425129Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425163Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID744343Inhibition of mouse PI3Kalpha2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
ISSN: 1464-3405
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
AID1425014Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425032Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424952Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425208Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425207Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425209Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425173Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425111Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424923Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424941Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425040Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425178Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425001Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425055Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425087Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425054Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424983Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424894Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425070Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425003Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424899Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425028Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425085Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424898Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425022Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425204Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424984Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425046Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425142Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1188623Inhibition of PI3Kalpha (unknown origin) using PIP2/PS as substrate preincubated for 15 mins before substrate addition by luciferase-based luminescence assay2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
ISSN: 1464-3405
Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
AID1425029Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425030Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425060Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424987Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424944Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425153Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425007Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424932Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425122Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425149Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424909Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425123Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425063Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425080Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425069Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425197Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425157Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425121Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424946Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1355490Cytotoxicity against human NCI-H460 cells after 96 hrs by MTT assay2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
ISSN: 1520-4804
Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.
AID1425191Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425050Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425034Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424960Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425026Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1850140Antibacterial activity against Escherichia coli 25922 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method2022RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1
ISSN: 2632-8682
Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1425057Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425182Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425008Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425137Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425105Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424998Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425048Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424977Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424974Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425053Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID744331Drug metabolism in human plasma assessed as formation of glucuronide conjugate at 8 mg, po qd for 21 days by HPLC analysis2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
ISSN: 1464-3405
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
AID1424914Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425187Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425193Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424999Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425079Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425177Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424940Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425100Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424900Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424962Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424986Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425074Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425004Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425017Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425082Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1871783Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system using L-alpha-phosphatidylinositol as substrate by luminescence assay2022European journal of medicinal chemistry, Jan-15, Volume: 228ISSN: 1768-3254Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.
AID1425179Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424912Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425078Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425116Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425117Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425018Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425094Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2014Protein science : a publication of the Protein Society, Oct, Volume: 23, Issue:10
ISSN: 1469-896X
Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.
AID1345749Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (Phosphatidylinositol kinases)2011ACS medicinal chemistry letters, Nov-10, Volume: 2, Issue:11
ISSN: 1948-5875
Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.
AID1345726Human mechanistic target of rapamycin kinase (FRAP subfamily)2011ACS medicinal chemistry letters, Nov-10, Volume: 2, Issue:11
ISSN: 1948-5875
Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (55.56)24.3611
2020's8 (44.44)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
fasudilisoquinolines;
N-sulfonyldiazepane
antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
201720177.0low000010
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline201720177.0low000010
imatinibaromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
201720177.0low000010
methicillinpenicillin allergen;
penicillin
antibacterial drug202220222.0low000001
trimetazidinearomatic amine201820186.0low000010
paclitaxeltaxane diterpenoid;
tetracyclic diterpenoid
antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
201820186.0low000010
triciribine phosphate201720177.0low000010
picropodophyllinfuronaphthodioxole;
lignan;
organic heterotetracyclic compound
antineoplastic agent;
insulin-like growth factor receptor 1 antagonist;
plant metabolite;
tyrosine kinase inhibitor
201720177.0low000010
gefitinibaromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
201720177.0low000010
lestaurtinibindolocarbazole201720177.0low000010
perifosineammonium betaine;
phospholipid
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor201720177.0low000010
vatalanibmonochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
ruboxistaurin201720177.0low000010
canertinibmonochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
cyc 2022,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720177.0low000010
enzastaurinindoles;
maleimides
201720177.0low000010
erlotinibaromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound
antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
201720177.0low000010
lapatinibfurans;
organochlorine compound;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
sorafenib(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide
angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
201720177.0low000010
s 1033(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
xl147aromatic amine;
benzothiadiazole;
quinoxaline derivative;
sulfonamide
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
201720177.0low000010
bms 3870321,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720177.0low000010
sf 2370bridged compound;
gamma-lactam;
methyl ester;
organic heterooctacyclic compound
antimicrobial agent;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
tropomyosin-related kinase B receptor antagonist
201720177.0low000010
tandutinibaromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
dasatinib1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
ha 1100201720177.0low000010
7-epi-hydroxystaurosporine201720177.0medium000010
zd 6474aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
imd 0354benzamides201720177.0low000010
sirolimusantibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol
antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
201720177.0low000010
alvocidibdihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720177.0low000010
bosutinibaminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
orantinib201720177.0low000010
su 11248monocarboxylic acid amide;
pyrroles
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
palbociclibaminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720177.0low000010
vx680N-arylpiperazine201720177.0low000010
cyc 116201720177.0low000010
everolimuscyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol
anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
201720177.0low000010
ekb 569aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile
protein kinase inhibitor201720177.0low000010
axitinibaryl sulfide;
benzamides;
indazoles;
pyridines
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
temsirolimusmacrolide lactam201720177.0low000010
on 01910N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycineantineoplastic agent;
apoptosis inducer;
EC 2.7.11.21 (polo kinase) inhibitor;
microtubule-destabilising agent
201720177.0low000010
av 412201720177.0low000010
telatinib201720177.0low000010
y-39983pyrrolopyridine201720177.0low000010
cp 547632201720177.0low000010
lenvatinibaromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
pd 0325901difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound
antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
201720177.0low000010
midostaurinbenzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
201720177.0low000010
cp 91149202220222.0low000001
px-866acetate ester;
delta-lactone;
organic heterotetracyclic compound;
tertiary amino compound
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor201720177.0low000010
ripasudilisoquinolines201720177.0medium000010
osi 930aromatic amide201720177.0low000010
scio-469aromatic amide;
aromatic ketone;
chloroindole;
dicarboxylic acid diamide;
indolecarboxamide;
monofluorobenzenes;
N-acylpiperazine;
N-alkylpiperazine
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720177.0low000010
cp 7247142-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamideantineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
hepatotoxic agent
201720177.0low000010
pi103aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
201820186.0low000010
hmn-214201720177.0medium000010
tivozanibaromatic ether201720177.0low000010
hki 272nitrile;
quinolines
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
tofacitinibN-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound
antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
201720177.0low000010
cediranibaromatic ether201720177.0low000010
masitinib1,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines
antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor
201720177.0low000010
ly-2157299aromatic amide;
methylpyridines;
monocarboxylic acid amide;
pyrrolopyrazole;
quinolines
antineoplastic agent;
TGFbeta receptor antagonist
201720177.0low000010
pazopanibaminopyrimidine;
indazoles;
sulfonamide
angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
azd 6244benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720177.0low000010
su 14813201720177.0low000010
cp-673,451aminoquinoline202220222.0low000001
bibw 2992aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
binimetinibbenzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monofluorobenzenes;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720177.0low000010
sotrastaurinindoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines
anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent
201720177.0low000010
aee 7886-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug
201720177.0low000010
saracatinibaromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound
anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
201720177.0low000010
vx 702phenylpyridine201720177.0low000010
crenolanibaminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
tg100-115pteridines201720177.0low000010
cc 401pyrazoles;
ring assembly
201720177.0low000010
bms 599626201720177.0low000010
exel-7647201720177.0low000010
volasertib201720177.0low000010
azd 7762aromatic amide;
thiophenes
201720177.0low000010
regorafenib(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide
antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
201720177.0low000010
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-onemethoxybenzenes;
substituted aniline
201720177.0low000010
brivanibaromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
201720177.0low000010
mp470N-arylpiperazine201720177.0low000010
rgb 286638201720177.0medium000010
np 031112benzenes;
naphthalenes;
thiadiazolidine
anti-inflammatory agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
201720177.0low000010
at 7519dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720177.0low000010
bms-690514201720177.0low000010
bi 2536201720177.0low000010
inno-406biaryl201720177.0low000010
kw 2449201720177.0low000010
danusertibpiperazines201720177.0low000010
abt 869aromatic amine;
indazoles;
phenylureas
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
azd 8931aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
tertiary amino compound
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
201720177.0low000010
arq 197indoles201720177.0low000010
azd 1152anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
Aurora kinase inhibitor;
prodrug
201720177.0low000010
pf 00299804enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
201720177.0low000010
ridaforolimusmacrolide lactam201720177.0low000010
quisinostatindoles202220222.0low000001
ch 4987655201720177.0high000010
6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylprpyl)-3-pyridinecarboxamidephenylpyridine201720177.0medium000010
cc-930201720177.0medium000010
tak 285201720177.0low000010
idelalisibaromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
201720177.0low000010
crizotinib3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
osi 906cyclobutanes;
quinolines
201720177.0low000010
chir-265aromatic ether201720177.0low000010
motesanibpyridinecarboxamide201720177.0low000010
fostamatinib201720177.0low000010
trametinibacetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
201720177.0low000010
mln8054benzazepine201720177.0low000010
pf-562,271indoles201720177.0low000010
jnj-26483327201720177.0high000010
ly2603618ureas201720177.0low000010
tg100801201720177.0medium000010
dactolisibimidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
201720224.5low000011
bgt226aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
201720224.5medium000011
gsk 461364(trifluoromethyl)benzenes201720177.0low000010
azd 1152-hqpaanilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
Aurora kinase inhibitor
201720177.0low000010
enmd 2076201720177.0low000010
e 7050aromatic ether201720177.0low000010
2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinonepyrazolopyridine201720224.5high000011
tak-901201720177.0low000010
gdc-0973aromatic amine;
difluorobenzene;
N-acylazetidine;
organoiodine compound;
piperidines;
secondary amino compound;
tertiary alcohol
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720177.0low000010
buparlisibaminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
201720177.0low000010
azd 1480201720177.0low000010
azd8330pyridinecarboxamide201720177.0low000010
pha 848125201720177.0low000010
ro5126766aryloxypyrimidine;
coumarins;
organofluorine compound;
pyridines;
sulfamides
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720177.0low000010
fedratinibsulfonamide201720177.0low000010
gsk6906931,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
201720177.0low000010
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene201720177.0low000010
azd5438sulfonamide201720177.0low000010
pf 04217903quinolines201720177.0low000010
gdc 0941indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor201720177.0low000010
icotinib201720177.0low000010
ph 797804aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720177.0low000010
kx-01201720177.0low000010
mk 5108aromatic ether201720177.0low000010
cx 4945201720177.0low000010
cudc 101201720177.0low000010
arry-614201720177.0medium000010
tak 593201720177.0medium000010
mln 8237benzazepine201720177.0low000010
sgx 523aryl sulfide;
biaryl;
pyrazoles;
quinolines;
triazolopyridazine
c-Met tyrosine kinase inhibitor;
nephrotoxic agent
201720177.0low000010
bms 754807pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
bms 777607aromatic amide201720177.0low000010
sgi 1776imidazoles201720177.0low000010
pci 32765acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide
antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
201720177.0low000010
ponatinib(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
amg 900201720177.0low000010
mk-1775piperazines201720177.0low000010
AMG-208aromatic ether;
quinolines;
triazolopyridazine
antineoplastic agent;
c-Met tyrosine kinase inhibitor
201720177.0low000010
quizartinibbenzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
201720177.0low000010
at13148201720177.0low000010
tak 733201720177.0low000010
mk 2206organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor201720177.0low000010
sns 314ureas201720177.0low000010
pc190723202220222.0low000001
lucitanibaromatic ether;
cyclopropanes;
naphthalenecarboxamide;
primary amino compound;
quinolines
antineoplastic agent;
fibroblast growth factor receptor antagonist;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamideaminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound
anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
201720177.0low000010
dcc-2036organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines
tyrosine kinase inhibitor201720177.0low000010
cabozantinibaromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
defactinib201720177.0low000010
ly2584702201720177.0low000010
incb-018424nitrile;
pyrazoles;
pyrrolopyrimidine
antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
201720177.0low000010
poziotinibacrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline
antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist
201720177.0low000010
asp3026aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone
antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor
201720177.0low000010
entrectinibbenzamides;
difluorobenzene;
indazoles;
N-methylpiperazine;
oxanes;
secondary amino compound;
secondary carboxamide
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
pexidartinibaminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
TAK-5801,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
201720177.0low000010
gsk 2126458aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent
201720224.5low000011
emd1214063201720177.0low000010
pf 3758309organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
201720177.0low000010
gdc 0980201720177.0medium000010
azd2014201720177.0low000010
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanolbenzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
mTOR inhibitor
201720177.0low000010
plx4032aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide
antineoplastic agent;
B-Raf inhibitor
201720177.0low000010
gsk 1363089aromatic ether201720177.0low000010
arry-334543201720177.0low000010
kin-193pyridopyrimidine201720177.0low000010
mk 2461201720177.0low000010
bay 869766201720177.0low000010
as 703026pyridinecarboxamide201720177.0low000010
pf 04929113202220222.0low000001
baricitinibazetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide
anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
201720177.0low000010
dabrafenib1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
201720177.0low000010
pki 587201720224.5low000011
n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide201720177.0low000010
ribociclib201720177.0low000010
mk-8033201720177.0low000010
pha 793887piperidinecarboxamide201720177.0low000010
sb 1518201720177.0low000010
abemaciclib201720177.0low000010
mk-8776201720177.0medium000010
afuresertibamphetamines201720177.0low000010
gsk 1070916pyrazoles;
ring assembly
201720177.0low000010
jnj38877605quinolines201720177.0low000010
dinaciclibpyrazolopyrimidine201720177.0low000010
gilteritinibaromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
alectinibaromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
glpg0634201720177.0low000010
encorafenib201720177.0low000010
bms-911543201720177.0low000010
pf-49892162011201113.0medium000010
gsk2141795201720177.0low000010
pf-4708671202220222.0low000001
azd8186201720177.0low000010
byl719proline derivative201720177.0low000010
cep-32496201720177.0low000010
pf-5274857202220222.0low000001
rociletinib201720177.0low000010
ceritinibaminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
azd1208201720177.0low000010
vx-509201720177.0low000010
debio 1347201720177.0low000010
volitinib201720177.0medium000010
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamidequinazolines202220222.0low000001
osimertinibacrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
201720177.0low000010
at 9283201720177.0low000010
otssp167201720177.0low000010
chir 258201720177.0low000010
osi 027201720177.0low000010
nintedanib201720177.0low000010
bay 80-6946201720177.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Acute Myelogenous Leukemia0201720177.0low000010
Benign Neoplasms0202220222.0low000001
Cancer of Lung0201720186.5medium000020
Congenital Zika Syndrome0202020204.0low000010
Disease Models, Animal0202020204.0low000010
Leukemia, Myeloid, Acute0201720177.0low000010
Lung Neoplasms0201720186.5medium000020
Neoplasms0202220222.0low000001
Zika Virus Infection0202020204.0low000010

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5
2019